Literature DB >> 20377979

Periprocedural bleeding complications of brain AVM embolization with Onyx.

L Liu1, C Jiang, H He, Y Li, Z Wu.   

Abstract

UNLABELLED: The advent of Onyx has provided a new method for neurointerventional therapists to treat brain AVMs. Although some retrospective studies have reported complications for AVM embolization with Onyx, periprocedural bleeding complications with Onyx embolization have not yet been described in detail. The aim of this retrospective study was to analyze the factors of Onyx-related bleeding complications and to find a way to avoid and manage these complications.From January 2003, patients with AVMs recruited in our institution started to be treated by Onyx embolization. From January 2007 to July 2009, 143 consecutive interventions were performed in 126 patients using flow-independent microcatheters and Onyx as embolic agents. Seven patients encountered bleeding complications (5.4% per patients and 4.7% per procedures) during or after the endovascular procedures. Among them, five bleeding episodes occurred during procedures, the other two after procedures. Details of the seven patients' clinical presentations, imaging presentations, speculative reasons and management of these complications were recorded. Follow-up data, including postoperative course, clinical symptoms and duration of follow-up were documented. The five active bleedings discovered in procedures were managed in time, and the patients recovered without any new neurological symptoms compared with preoperation. However, of the two bleeding episodes that occurred after interventional procedures, one was detected half an hour later: the patient was remained comatose two months later after resection of right occipital hematoma; the other who encountered intraventricular and midbrain hemorrhage was treated conservatively and suffered Parinaud syndrome and hemianesthesia.
CONCLUSION: Periprocedural bleeding of AVMs embolization is considered a severe and devastating complication. The clinical course and prognosis of bleeding mostly depends on prompt detection and management. Interventional embolization is an effective method to manage bleeding during procedures, and the detection of risk factors and imaging signs of bleeding is extremely important.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20377979      PMCID: PMC3277965          DOI: 10.1177/159101991001600106

Source DB:  PubMed          Journal:  Interv Neuroradiol        ISSN: 1591-0199            Impact factor:   1.610


  28 in total

1.  Determinants of neurological outcome after surgery for brain arteriovenous malformation.

Authors:  A Hartmann; C Stapf; C Hofmeister; J P Mohr; R R Sciacca; B M Stein; A Faulstich; H Mast
Journal:  Stroke       Date:  2000-10       Impact factor: 7.914

2.  Arteriovenous malformations of the brain: ready to randomise?

Authors:  R Al-Shahi; C Warlow
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-10       Impact factor: 10.154

3.  Brain AVM embolization with Onyx.

Authors:  W J van Rooij; M Sluzewski; G N Beute
Journal:  AJNR Am J Neuroradiol       Date:  2007-01       Impact factor: 3.825

4.  Nidal embolization of brain arteriovenous malformations using Onyx in 94 patients.

Authors:  C Mounayer; N Hammami; M Piotin; L Spelle; G Benndorf; I Kessler; J Moret
Journal:  AJNR Am J Neuroradiol       Date:  2007-03       Impact factor: 3.825

5.  Endovascular treatment of intracranial arteriovenous malformations with onyx: technical aspects.

Authors:  W Weber; B Kis; R Siekmann; D Kuehne
Journal:  AJNR Am J Neuroradiol       Date:  2007-02       Impact factor: 3.825

6.  Risk of endovascular treatment of brain arteriovenous malformations.

Authors:  A Hartmann; J Pile-Spellman; C Stapf; R R Sciacca; A Faulstich; J P Mohr; H C Schumacher; H Mast
Journal:  Stroke       Date:  2002-07       Impact factor: 7.914

7.  Curative embolization of cerebral arteriovenous malformations (AVMs) with Onyx in 101 patients.

Authors:  Vasilios Katsaridis; Chrysanthi Papagiannaki; Enrico Aimar
Journal:  Neuroradiology       Date:  2008-04-12       Impact factor: 2.804

8.  The safety and effectiveness of brain arteriovenous malformation embolization using acrylic and particles: the experiences of a single institution.

Authors:  R C Wallace; R A Flom; M H Khayata; B L Dean; J McKenzie; J C Rand; N A Obuchowski; R C Zepp; J M Zabramski; R F Spetzler
Journal:  Neurosurgery       Date:  1995-10       Impact factor: 4.654

9.  Severe intracranial bleedings during endovascular procedures: outcome of surgically treated patients.

Authors:  Mario Carvi y Nievas; Eberhard Haas; Hans-Georg Höllerhage
Journal:  Neurol Res       Date:  2007-01       Impact factor: 2.448

10.  [Clinical experience of 70 cases of cerebral arteriovenous malformations embolization with Onyx, a novel liquid embolic agent].

Authors:  Dong-Lei Song; Bing Leng; Bin Xu; Qi-Hong Wang; Xian-Cheng Chen; Liang-Fu Zhou
Journal:  Zhonghua Wai Ke Za Zhi       Date:  2007-02-15
View more
  4 in total

1.  Microcatheter entrapment retrieval from Onyx embolization in brain arteriovenous malformations: A technical note.

Authors:  Phat D Vu; Arthur A Grigorian
Journal:  Interv Neuroradiol       Date:  2015-07-31       Impact factor: 1.610

2.  Assessment of periprocedural hemodynamic changes in arteriovenous malformation vessels by endovascular dual-sensor guidewire.

Authors:  Kirill Orlov; Vyacheslav Panarin; Alexey Krivoshapkin; Dmitry Kislitsin; Vadim Berestov; Timur Shayakhmetov; Anton Gorbatykh
Journal:  Interv Neuroradiol       Date:  2015-02       Impact factor: 1.610

3.  Unexpected silent infarctions after embolization of cerebral arteriovenous malformations and fistulas. A diffusion-weighted magnetic resonance imaging study.

Authors:  L Suazo; C Putman; C Vilchez; P Stoeter
Journal:  Interv Neuroradiol       Date:  2013-05-21       Impact factor: 1.610

4.  Intra- and post-operative acute hemorrhagic complications of Onyx embolization of brain arteriovenous malformations: A single-center experience.

Authors:  Xuan Chen; Yiheng Wang; Jinlu Yu
Journal:  Front Neurol       Date:  2022-09-23       Impact factor: 4.086

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.